Analysts Set GSK PLC Sponsored ADR (NYSE:GSK) PT at $53.00

GSK PLC Sponsored ADR (NYSE:GSK) has received a consensus rating of “Hold” from the ten research firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $53.00.

Several equities research analysts recently commented on the company. HSBC raised GSK from a “reduce” rating to a “hold” rating in a research note on Monday, July 6th. Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research report on Thursday, July 9th. Wall Street Zen upgraded shares of GSK from a “hold” rating to a “buy” rating in a research report on Saturday, June 27th. Finally, Weiss Ratings lowered shares of GSK from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 11th.

Institutional Trading of GSK

Large investors have recently made changes to their positions in the company. First Horizon Corp increased its position in GSK by 78.7% in the 4th quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 236 shares in the last quarter. Elyxium Wealth LLC bought a new position in GSK in the fourth quarter worth approximately $30,000. Triumph Capital Management acquired a new stake in GSK in the third quarter valued at approximately $40,000. 1248 Management LLC grew its stake in GSK by 314.6% in the third quarter. 1248 Management LLC now owns 1,053 shares of the pharmaceutical company’s stock valued at $46,000 after acquiring an additional 799 shares during the period. Finally, Coston McIsaac & Partners increased its holdings in shares of GSK by 17.3% during the fourth quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock valued at $68,000 after acquiring an additional 206 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Performance

GSK stock opened at $52.77 on Friday. The firm has a market cap of $106.73 billion, a PE ratio of 13.71, a price-to-earnings-growth ratio of 3.29 and a beta of 0.35. The company has a current ratio of 0.79, a quick ratio of 0.52 and a debt-to-equity ratio of 0.80. The stock has a 50-day moving average price of $51.52 and a 200-day moving average price of $53.35. GSK has a 1-year low of $35.45 and a 1-year high of $61.69.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 9th. Stockholders of record on Friday, May 15th were issued a dividend of $0.44 per share. The ex-dividend date was Friday, May 15th. This represents a $1.76 annualized dividend and a dividend yield of 3.3%. GSK’s dividend payout ratio is currently 46.49%.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.